Vicriviroc + MK2048 + Progestin Vaginal Ring

Description: A vaginal ring whose mechanism of action is CCR5 inhibitor, integrase inhibitor and a progestin for protection against HIV and pregnancy.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Vaginal Ring

Active Pharmaceutical Ingredient (API):
  • MK2048
  • progestin
  • Vicriviroc

Inactive material: EVA

Multipurpose Preventive Technology (MPT): Yes

Status Details

Developer: DAIDS, Merck, NIAID

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Pre-clinical

Active Development: Unknown

Status Details:
  • Phase I study of 2-ARV IVR prototype completed in 2016.
  • Merck announced that it would discontinue development of its investigational CCR5 antagonist vicriviroc for the treatment of HIV infection in both treatment-naive and treatment-experienced patients, due to unimpressive results in clinical trials.

Additional Information

Footnotes:
  • Vicriviroc is also known as MK4176.

Vertical Tabs

Print